The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 15, 2013
Filed:
Oct. 14, 2011
Jianghe Deng, King of Prussia, PA (US);
Jeffrey K. Kerns, King of Prussia, PA (US);
Qi Jin, King of Prussia, PA (US);
Guoliang Lin, King of Prussia, PA (US);
Xichen Lin, King of Prussia, PA (US);
Michael Lindenmuth, King of Prussia, PA (US);
Christopher Neipp, King of Prussia, PA (US);
Hong Nie, King of Prussia, PA (US);
Sonia M Thomas, King of Prussia, PA (US);
Katherine L. Widdowson, King of Prussia, PA (US);
Jianghe Deng, King of Prussia, PA (US);
Jeffrey K. Kerns, King of Prussia, PA (US);
Qi Jin, King of Prussia, PA (US);
Guoliang Lin, King of Prussia, PA (US);
Xichen Lin, King of Prussia, PA (US);
Michael Lindenmuth, King of Prussia, PA (US);
Christopher Neipp, King of Prussia, PA (US);
Hong Nie, King of Prussia, PA (US);
Sonia M Thomas, King of Prussia, PA (US);
Katherine L. Widdowson, King of Prussia, PA (US);
GlaxoSmithKline LLC, Philadelphia, PA (US);
Abstract
The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.